Carisma Therapeutics, Inc.

NasdaqGM:CARM Stock Report

Market Cap: US$19.9m

Carisma Therapeutics Past Earnings Performance

Past criteria checks 0/6

Carisma Therapeutics's earnings have been declining at an average annual rate of -22.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 69.3% per year.

Key information

-22.8%

Earnings growth rate

67.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate69.3%
Return on equityn/a
Net Margin-314.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Dec 06
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Revenue & Expenses Breakdown

How Carisma Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:CARM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2420-64240
30 Jun 2421-73250
31 Mar 2415-81250
31 Dec 2315-87300
30 Sep 2314-83230
30 Jun 2313-80200
31 Mar 2312-75170
31 Dec 2210-6190
30 Sep 226-57110
30 Jun 224-4990
31 Mar 221-4380
31 Dec 210-4160

Quality Earnings: CARM is currently unprofitable.

Growing Profit Margin: CARM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CARM is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.

Accelerating Growth: Unable to compare CARM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CARM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).


Return on Equity

High ROE: CARM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/27 16:56
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carisma Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Justin ZelinBTIG
Naureen QuibriaCapital One Securities, Inc.